2. Signaling Pathways
  3. MAPK/ERK Pathway
  4. MEK

MEK

Mitogen-activated protein kinase kinase; MAPKK; MAP2K

MEK

Related Products

PDF 1.0 MB

MEK (Mitogen-activated protein kinase kinase, MAPKK) is a kinase enzyme which phosphorylates mitogen-activated protein kinases (MAPKs). The activated MAPK leads to the phosphorylation of downstream transcription factors that regulate various responses such as stress signaling, pathogen response, and hormone signaling.

In general, the MAPKKK phosphorylates a serine or threonine residue on a MAPKK, which sequentially activates a MAPK (ERK, p38 or JNK), the last protein in the cascade. Activation of the p38 MAPK occurs mainly through mitogen-activated protein kinase kinase 3 (MKK3) and MKK6 (sometimes MKK4). The JNK is regulated by two upstream MAP2Ks: MKK4 and MKK7. The highly homologous kinases, MEK1 and MEK2, act downstream of Ras and Raf to activate ERK mitogen-activated protein kinases.

MEK Isoform Specific Products:

MEK Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-173153
    BRAFV600E/JNK-IN-1
    		Inhibitor
    BRAFV600E/JNK-IN-1 (Compound 14c) is an inhibitor of JNK1, JNK2, JNK3 and BRAFV600E, with IC50 values of 0.51 μM, 0.53 μM, 1.02 μM and 0.009 μM, respectively. BRAFV600E/JNK-IN-1 can inhibit the phosphorylation of MEK1/2 and ERK1/2. In addition, BRAFV600E/JNK-IN-1 can inhibit tumor cell proliferation, NO release and PGE2 production, and has anti-tumor and anti-inflammatory activities.
    BRAFV600E/JNK-IN-1
  • HY-12447
    SMK-17
    		Inhibitor
    SMK-17 is a selective, non-ATP-competitive MEK1/MEK2 inhibitor with IC50s of 62 nM and 56 nM, respectively. SMK-17 binds to the allosteric pocket of MEK1/2. SMK-17 induces apoptosis in tumor cell lines harboring β-catenin mutations.
    SMK-17
  • HY-RS08038
    Map2k2 Rat Pre-designed siRNA Set A
    		Inhibitor

    Map2k2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Map2k2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Map2k2 Rat Pre-designed siRNA Set A
    Map2k2 Rat Pre-designed siRNA Set A
  • HY-10508
    (R)-PD 0325901CL
    		Inhibitor
    (R)-PD 0325901CL is an isomer of PD 0325901CL. PD 0325901CL is a selective inhibitor of mitogen-activated protein kinase kinase (MEK) involved in cancer research. PD 0325901CL inhibits the growth of cancer cells in vitro and in vivo.
    (R)-PD 0325901CL
  • HY-RS08042
    Map2k5 Mouse Pre-designed siRNA Set A
    		Inhibitor

    Map2k5 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Map2k5 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Map2k5 Mouse Pre-designed siRNA Set A
    Map2k5 Mouse Pre-designed siRNA Set A
  • HY-164474
    DS03090629
    		Inhibitor
    DS03090629 is an orally active MEK inhibitor that inhibits MEK activity in an ATP-competitive manner. DS03090629 exhibits high affinity for both MEK and phosphorylated MEK, with Kd values of 0.11 and 0.15 nM, respectively. It effectively inhibits the proliferation of BRAF-mutant overexpressing melanoma cell lines, with IC50 values of 74.3 and 97.8 nM for BRAF V600E and MEK1 F53L transfected A375 cells, respectively. DS03090629 holds potential value in the field of anti-melanoma therapy.
    DS03090629
  • HY-RS08041
    MAP2K5 Human Pre-designed siRNA Set A
    		Inhibitor

    MAP2K5 Human Pre-designed siRNA Set A contains three designed siRNAs for MAP2K5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    MAP2K5 Human Pre-designed siRNA Set A
    MAP2K5 Human Pre-designed siRNA Set A
  • HY-B0185BR
    Lidocaine hydrochloride hydrate (Standard)
    		Inhibitor
    Lidocaine (hydrochloride hydrate) (Standard) is the analytical standard of Lidocaine (hydrochloride hydrate). This product is intended for research and analytical applications. Lidocaine (Lignocaine) hydrochloride hydrate inhibits sodium channels involving complex voltage and using dependence. Lidocaine hydrochloride hydrate decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride hydrate is an amide derivative and has potential for the research of ventricular arrhythmia.
    Lidocaine hydrochloride hydrate (Standard)
  • HY-137881
    MEK-IN-4
    		Inhibitor
    MEK-IN-4 is a MEK inhibitor. MEK-IN-4 can be used for the research of inflammatory disorders and cancers.
    MEK-IN-4
  • HY-19700R
    trans-Zeatin (Standard)
    		Inhibitor
    trans-Zeatin (Standard) is the analytical standard of trans-Zeatin. This product is intended for research and analytical applications. trans-Zeatin is a plant cytokinin, which plays an important role in cell growth, differentiation, and division; trans-Zeatin also inhibits UV-induced MEK/ERK activation.
    trans-Zeatin (Standard)
  • HY-10999S2
    Trametinib-13C,d3
    		Inhibitor
    Trametinib-13C,d3 is the 13C- and deuterium labeled Trametinib. Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. Trametinib activates autophagy and induces apoptosis.
    Trametinib-<sup>13</sup>C,d<sub>3</sub>
  • HY-RS08034
    Map2k1 Mouse Pre-designed siRNA Set A
    		Inhibitor

    Map2k1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Map2k1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Map2k1 Mouse Pre-designed siRNA Set A
    Map2k1 Mouse Pre-designed siRNA Set A
  • HY-P10832
    ATWLPPRAANLLMAAS
    		Inhibitor
    ATWLPPRAANLLMAAS is a chimeric peptide with anti-angiogenic and potent anti-tumor effects. ATWLPPRAANLLMAAS can inhibit the proliferation, viability, migration, and invasion of human hepatocellular carcinoma cells, and induce apoptosis..
    ATWLPPRAANLLMAAS
  • HY-153864
    PROTAC MEK1 Degrader-1
    		Inhibitor
    PROTAC MEK1 Degrader-1 is a PROTAC targeting MEK1 with a pIC50 value of 7.0. PROTAC MEK1 Degrader-1 consists of a MEK1 inhibitor and a von Hippel-Lindau ligand. PROTAC MEK1 Degrader-1 can inhibit ERK1/2 phosphorylation. PROTAC MEK1 Degrader-1 shows an antiproliferative activity against A375 cells.
    PROTAC MEK1 Degrader-1
  • HY-153445A
    MEK-IN-6 hydrate
    		Inhibitor
    MEK-IN-6 hydrate (compound 69) is a MEK inhibitor. MEK-IN-6 hydrate has an IC50 of 2 nM for A375 cells.
    MEK-IN-6 hydrate
  • HY-13064R
    Cobimetinib (Standard)
    		Inhibitor
    Cobimetinib (Standard) is the analytical standard of Cobimetinib. This product is intended for research and analytical applications. Cobimetinib (GDC-0973, RG7420) is a potent, selective and oral MEK1 inhibitor with an IC50 of 4.2 nM for MEK1.
    Cobimetinib (Standard)
  • HY-164529
    SJ-C1044
    SJ-C1044 is an orally available pan-RAF inhibitor with immunomodulatory and anti-tumor activities. SJ-C1044 inhibits wild-type BRAF, wild-type CRAF, and BRAF (V600E) with IC50 values ??of 331, 257, and 187 nM, respectively. SJ-C1044 inhibits tumor cell proliferation by inhibiting kras activation and MEK-ERK phosphorylation. In addition, SJ-C1044 also has a certain inhibitory effect on VEGFR2, TIE2, and CSF1R, with IC50 values ??of 100, 23, and 235 nM, respectively. SJ-C1044 improves the tumor immune microenvironment by inhibiting angiogenesis and regulating macrophage function. SJ-C1044 can be used in the study of colorectal cancer.
    SJ-C1044
  • HY-P0119S
    Lixisenatide (Leu-13C6,15N) TFA
    Lixisenatide (Leu-13C6,15N) TFA is the 13C- and 15N-labeled Lixisenatide (HY-P0119). Lixisenatide is a GLP-1 receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of proinflammatory cytokines, and blocks of cellular signaling pathways. Lixisenatide decreases atheroma plaque size and instability in Apoe?/? Irs2+/? mice by reprogramming macrophages towards an M2 phenotype, which leads to reduced inflammation.
    Lixisenatide (Leu-<sup>13</sup>C<sub>6</sub>,<sup>15</sup>N) TFA
  • HY-N6670R
    Cefotetan (Standard)
    		Activator
    Cefotetan (Standard) is the analytical standard of Cefotetan. This product is intended for research and analytical applications. Cefotetan is a semisynthetic cephamycin antibiotic that exerts its bactericidal effects by inhibition of cell-wall synthesis.
    Cefotetan (Standard)
  • HY-B0185S
    N-Oxide Lidocaine-d10
    		Inhibitor
    N-Oxide Lidocaine-d10 is the deuterium labeled Lidocaine. Lidocaine (Lignocaine) inhibits sodium channels involving complex voltage and using dependence. Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia.
    N-Oxide Lidocaine-d<sub>10</sub>
Cat. No. Product Name / Synonyms Application Reactivity
MEK Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.